ANZTCT Position Statement: COVID-19 Management in Haematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T cell Patients.
Jacinta PerramDuncan PurtillAshish BajelJason ButlerTracey O'BrienBenjamin W TehNicole GilroyPhoebe J HoRichard DooceyThomas HillsTravis PereraGenevieve DouglasShanti RamachadranLynette CheeJudith TrotmanRobert WeinkoveSteven KeoghChris FraserTara CochraneAnne-Marie WatsonPeter DiamondMaya LatimerIan IrvingEmily BlythChan CheahTheresa ColeSam MillikenHung YangMatthew GreenwoodPeter BardyGlen KennedyStephen LarsenRachel ConyersNada HamadPublished in: Internal medicine journal (2022)
Patients post haematopoietic stem cell transplant or CAR-T cell therapy face significant risk of morbidity and mortality from SARS-CoV19, due to their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learnt much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to optimally manage our patients. This article is protected by copyright. All rights reserved.